期刊文献+

泰索帝在激素抵抗型前列腺癌治疗中研究进展 被引量:1

下载PDF
导出
摘要 激素抵抗型前列腺癌 (Hormonerefractoryprostatecancer,HRPC)是泌尿肿瘤学中最为复杂的问题之一[1 ] 。目前对HRPC的治疗极为有限 ,主要治疗策略是雄激素去势疗法 ,但该疗法疗效短 ,易产生激素耐药性。而泰索帝 (多西紫杉醇 )通过诱导肿瘤细胞凋亡可达到抗肿瘤作用 ,近年来 ,该方法在抗肿瘤方面的研究越来越深入 。
机构地区 [
出处 《国外医学(泌尿系统分册)》 2005年第2期145-147,共3页 Foreign Medical Sciences(Urology and Nephrology Foreign Medical Sciences)
  • 引文网络
  • 相关文献

参考文献8

  • 1Small EJ, Reese DM, Vogelzang NJ. Hormone - refractory prostate cancer:an evolving standard of care. Semin Oncol, 1999,26( 5 suppl 17):6767.
  • 2Khan MA, Carducci MA, Partin AW, et al. The evolving role of docetaxel in the management of androgen independent prostate cancer. J Urol,2003,170(5) :1709 - 16.
  • 3Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med,2004,351 (15): 1502 - 12.
  • 4Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med,2004,351 (15): 1513 - 20.
  • 5Walczak JR, Carducci MA. Eastern Cooperative Oncology Group E1899.Phase 3 randomized trial evaluating second- line hormonal therapy versus docetaxel- estramustine combination chemotherapy on progression- free survival in asymptomatic patients with a rising prostate - specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group(E1899), Intergroup/Clinical Trials Support Unit study.Urology,2003,62 Suppl 1:141-6.
  • 6Beer TM, Eilers KM, Garzotto M, et al. Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen - independent prostate carcinoma. Cancer, 2004, 100 (4): 758 -63.
  • 7Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase Ⅱ trial of docetaxel plus thalidomide in androgen - independent prostate cancer. J Clin Oncol, 2004,22(13) :2532 - 9.
  • 8Vordos D, Paule B, Vacherot F, et al. Docetaxel and zoledronic acid in patients with metastatie hormone- refractory prostate cancer. BJU Int,2004,94(4) :524 - 7.

同被引文献6

  • 1刘健,陈新华,洪熠,李重颖,刘非.卡培他滨联合多西紫杉醇治疗转移性乳腺癌的临床观察[J].中华肿瘤防治杂志,2006,13(16):1255-1256. 被引量:10
  • 2魏爱英,张庆柱,张捷.多西他赛诱导乳腺癌Bcap37细胞凋亡作用的研究[J].中华肿瘤防治杂志,2006,13(18):1384-1386. 被引量:10
  • 3Yagoda A, Petrylak D. Cylotoxic chemotherapy for advanced hormone-resistant prostate cancer[J]. Cancer, 1993, 71(Suppl 3): 1098-1109.
  • 4Bracarda S. Chemotherapy of postate cancer: potential role of docetaxel[J]. Tumori, 2001, 87(6): 12--14.
  • 5Cooper C R, Chay C H, Gendernalik J D, et al. Stromal factors in volved in prostate carcinoma metastasis to bone[J]. Cancer, 2003, 97(Supp 1): 739-747.
  • 6Nalbandian A, Djakiew D. The p75(NTR) metastasis suppressor inhibits urokinase plasminogen activator, matrix metallopro teinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells[J]. Clin Exp Metastasis, 2006,23(2):107--116.

引证文献1

二级引证文献5

;
使用帮助 返回顶部